Biocon has informed that it enclosed the press release titled ‘Biocon Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection, a Biosimilar to Perjeta®, Expanding Its Oncology Portfolio”. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.